@BenClickMD

IBD MD at University of Colorado. Clinician and researcher. Tweets my own. Retweet not endorsement.

Joined May 2018
  • Tweets523
  • Following260
  • Followers1.4K
65Media
‼️Important HBV reaction prevention in IBD pts. Note JAKi mod risk > aTNF in sAg(-), cAb(+) -> antiviral ppx. @GI_PharmD @JHashashMD @fudmanMD @Waseem_AhmedMD @IBDPharmD gastrojournal.org/article/S0…
31
71
7,250
Crowdsourcing IBD journal club ideas. What are your biggest clinical impact recent articles? @fudmanMD @DCharabaty @IBDimmunology @Waseem_AhmedMD @EdwardLoftus2 @MLongMD @Bealoquebea
8
2
1
21
3,885
Maybe time to just get the C diff test?
Elliot Tapper@ebtapper
3 May 2023
The first RCT of GI-PCR for acute diarrhea 👎more antibiotic use in PCR arm 👉no difference in any outcome 🤷‍♂️less time in isolation for PCR arm This test is 💩, friends Instead: Supportive care Test sparingly Mostly cdiff thelancet.com/action/showPdf…
1
4
23
6,844
Makes sense and highlights 💊💉needs after ASUC 🏥, but still high (~50%) rate of “treatment failure” in IVCS responsive -> IFX + AZA. ? rapid steroid taper in IFX. ? No proactive TDM in high risk pop. Other thoughts? @Waseem_AhmedMD @berinsj @IBDimmunology
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
3
2
8
2,654
🚨AGA New Guideline Alert🚨 🔗gastrojournal.org/article/S0… ▶️AGA Living Guideline: Pharmacological Management of Moderate-Severe Ulcerative Colitis I’ll break down its 14 recommendations down over the next 7 tweets 🧵 👇 #AGA #GI #UC #IBD #MedTwitter 1/9
9
106
6
325
38,883
First non aTNF to demonstrate efficacy in RCT to 🛑 endo recurrence. Good option and reassuring data to have.
Harry Sokol@h_sokol
19 Nov 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…
4
27
1,862
More RWE that combo-AT effective in refractory IBD (n=79) @jensemineriomd 🟢Mean Mayo 3▶️1 🟢Mean SES-CD 12▶️4 🟢73% clin improvement 🔴47% AEs (URIs and derm issues mostly) bit.ly/4fm80WI

Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease:...

AbstractBackground. Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), often results in significant morbidity am

academic.oup.com
2
11
932
Replying to @ABennettMD
@ABennettMD did an amazing job at #ACG2024 presenting a multi-center study evaluating outcomes in transgender pts with IBD on gender affirming hormones! @VUMCibd @VictorChedidMD @KiraNewmanMDPhD @JustinFieldMD @BenClickMD
2
10
540
🚨Fellows & jr attendings- Don't miss this on 9/18! 1⃣Find & negotiate your first or next GI/#IBD job, academic or community 2⃣Navigate career transitions or move to leadership 3⃣Q&A with those in the know @drharrythomas @Marylandibddoc @JillGaidosMD @BenClickMD Sign up 👇
2
16
3
40
6,937
It’s a packed 🏡 at #RMH2024! We are so thankful 🙌 for all of our amazing attendees and supporters for coming out bright ⭐️ and early 🌞on this Saturday!
4
13
1,136
Ever wonder if you should biopsy normal neoTI after resection in CD? ▶️Normal (i0) endoscopy ▶️Active inflammation ⬆️POR risk More evidence that active 🔬 disease can risk stratify IBD clinical risk. @RavShahMD @IBDBen @DrJordanAxelrad @EdBarnesMD journals.lww.com/ajg/abstrac…
3
16
1
43
4,015
What to do clinically with this info? ▶️Start/change meds? Probably not…yet ▶️Closer monitoring? I benchmark FC and then follow q3m with repeat CSY in one yr (or rising FC). IUS could be nice interval data here.
1
9
440
Kudos to @HolubarStefan for the excellent mesenteric landscape breakdown. SPICY trial an important addition, but still many unknowns in “trimming the Crohn’s fat” @CUGastroHep @ClevelandClinic
The Lancet Gastroenterology & Hepatology@LancetGastroHep
16 Jul 2024
Replying to @LancetGastroHep
Linked Comment - Click & Holubar - Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand? thelancet.com/journals/langa… #GITwitter #IBD @BenClickMD @HolubarStefan
9
17
2,313
Hot of the press: Upadacitinib safety in pregnancy. 128 maternal pregnacies all exposed in the first trimester primarily. @MotherToBaby @JulsgaardMette @MLongMD link.springer.com/article/10…

Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and...

Drug Safety - Upadacitinib is indicated for diseases affecting persons of childbearing potential including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis,...

link.springer.com
5
69
7
175
21,672
It’s dope to scope! 🤣First year fellows start scoping right away on inpatient consult services and on outpatient endo blocks. Follow our fellows on instagram @colorado_gi #futureofgi #gifellowship #gifellows #gastroenterology #academicgi
2
37
2,112
Thanks to @ShomronH for phenomenal talk on role of VCE - practice changing evidence from master clinician, researcher, and world traveler.
Shomron Ben-Horin@ShomronH
11 Jul 2024
Cool session at @CUGastroHep discussing use of #VCE in monitoring CD. Had great time with @MarkGerichMD (who ran off to scope before the pic was taken...) @FrankIScottMD @BenClickMD @Waseem_AhmedMD And the rest of fantastic U.Colorado team
2
18
2,036
#TaylorKarl with an outstanding presentation evaluating the cost-effectiveness of #calprotectin in post-op #CD monitoring. @BenClickMD @FrankIScottMD @IBDBen @DrJordanAxelrad @MRegueiroMD #DDW2024
7
1
29
2,365
Taylor Karl presenting our modeling data suggesting that fecal calprotectin monitoring reduces costs and improves quality of life in comparison to colonoscopic assessment in low risk post operative CD, supporting recently published guideline revisions @BenClickMD @CUGastroHep
3
17
650
37 yoM non-smoker, dx w stricturing ileal CD. Started on ADAL x1 yr then ICR ✂️for symptomatic 10 cm stricture. 🔬Path: Chronic active ileitis, margins clear. #MondayNightIBD What is your medical and monitoring post-op plan?
42%Meds + CSY in 6-12 mo
18%Meds + FCP/IUS in 6-12 mo
29%No Meds + CSY in 6-12 mo
12%No Meds + FCP/IUS 6-12 mo
129 votes • Final results
5
10
1
21
8,716
If planning postop meds, which one do you choose?
31%ADAL
21%IFX
34%USTE/RISA
14%VDZ
77 votes • Final results
2
2
6
685
How do you decide to stick with a pre🔪 💉 or change agents, MOAs?
3
171
For those that choose💉prophylaxis, what risk factors or 💭drove that decision? Who's doing non-invasive monitoring only? When and how often do you perform?
1
2
7
775
Load more